@article{Ronconi_Dondi_Piccinni_Calabria_Capponcelli_Pedrini_Marangolo_Esposito_Pinto_Martini_2021, title={Metastatic renal cancer: real-world evidence from a large Italian claims database}, volume={8}, url={https://journals.aboutscience.eu/index.php/grhta/article/view/2178}, DOI={10.33393/grhta.2021.2178}, abstractNote={<p class="abstract"><strong>Purpose: </strong>To assess the healthcare resources’ consumption and integrated costs of patients with renal cancer and new metastasis (mRCC), in the perspective of the Italian National Health System (NHS).</p> <p class="abstract"><strong>Methods:</strong> From the ReS database, through the administrative data record linkage, adults with a primary/secondary hospital (ordinary/daily admissions) diagnosis (ICD9-CM code) of renal cancer and lymph node and/or distant metastases in the same hospital discharge (index date) were selected in 2015. Metastases were defined new if they were absent in the 2 previous years. Patients were described in terms of gender, age (mean ± SD) and comorbidities of interest. The 2-year survival and annual pharmacological treatments, hospitalization, outpatient specialist services and costs were analysed.</p> <p class="abstract"><strong>Results:</strong> Out of >6 million adults in the 2015 ReS database, 133 (2.1 × 100,000) were hospitalized with a diagnosis of RCC and metastasis. Patients with new metastases were 63.2% (1.4 × 100,000; 73.8% males; mean age 68 ± 13). Hypertension was the most common comorbidity (70.2% of mRCC patients). The 2-year survival of mRCC patients was 26.2%. During 1-year follow-up, at least a drug was prescribed to 88.1% of mRCC patients (on average € 12,095/patient), 91.7% were hospitalized (€ 8,897/patient) and 82.1% entrusted the outpatient specialist care (€ 1,075/patient). The mean overall expenditure for the NHS was € 22,067 per capita.</p> <p class="abstract"><strong>Conclusions:</strong> This study shows the mRCC burden on the Italian real clinical practice and its economic impact in the perspective of the NHS. Real-world analyses prove to be useful to concretely estimate the overall healthcare responsibility on patients affected by mRCC.</p>}, number={1}, journal={Global and Regional Health Technology Assessment}, author={Ronconi, Giulia and Dondi, Letizia and Piccinni, Carlo and Calabria, Silvia and Capponcelli, Anna and Pedrini, Antonella and Marangolo, Maurizio and Esposito, Immacolata and Pinto, Carmine and Martini, Nello}, year={2021}, month={Feb.}, pages={1–7} }